Biologic Drugs in Development

The COVID-19 vaccines opened the door to powerful market potential for other nucleic acid-based therapies.

Takeda received approval in Japan for a subcutaneous injection formulation of Entyvio (vedolizumab) for treating ulcerative colitis.

BioNTech will receive an exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 mAb candidate for solid tumor indications.

The collaboration between Genuv and Celltrion will utilize Genuv's proprietary mouse platform for antibody discovery.

Some noteworthy PSGs include dihydroergotamine mesylate nasal spray, glucagon nasal powder, afamelanotide subcutaneous implant, and triamcinolone acetonide injectable suspension.

A slew of late-stage clinical trials is expected to push new regenerative medicines onto the market in the next few years.

The COVID-19 pandemic helped to showcase RNA molecules and their therapeutic potential. There were also lessons learned in terms of drug delivery, manufacturing, logistics, and storage.

Messenger RNA is inherently unstable and thus requires unique solutions to protect its cohesion.

Deeper biological understanding and technology innovations have improved the fate of ADC development.

The Start-Up Market at CPHI Barcelona brings together 27 start-ups, innovators, and small enterprises from across the pharma landscape.

A thorough understanding of both regulatory requirements and study challenges can help develop and validate the appropriate methods for a bioanalytical study program.

The clinical trial research environment has evolved because of specific solutions designed to overcome uncertainty.

Synthego has launched new engineered cell libraries to validate targets for quicker drug discovery timelines.

The growth in demand of viral-vector-based gene therapies drives continuous efforts to improve viral vector manufacturing.

Avoiding roadblocks through strategic planning early on can help facilitate IND application filings.

The recent approvals of bispecific antibodies have opened the gate for the further development of these complex molecules.

VeriSIM Life and Mayo Clinic are collaborating to develop new promising drug candidates.

LG Chem has decided to proceed with IND-enabling studies and has renewed a license with Avacta.

Finding specific solutions to overcome uncertainty has led to the evolution of a new clinical trial research environment.

ImmunoGen has formed a research collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates for cancers with high unmet needs.

Having a clear clinical strategy early on can shave time off overall development projects.

Advances in genomics tools can lead to quicker biotherapeutic development.

With recent approvals of bispecific antibodies, these complex molecules are fast moving out of the research box and into clinical pipelines.

Lonza and Israel Biotech Fund form a two-year agreement to support accelerated development and manufacture of biologics and small molecules.

A new initiative aims to speed the approval of and access to new drugs for young patients around the world, while limiting the number of children needed for testing in clinical trials.